Semaglutide subcutaneous - Novo Nordisk

Drug Profile

Semaglutide subcutaneous - Novo Nordisk

Alternative Names: 9931; NN-9535; NN-9536; NN9931; NNC-0113-0217

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 20 Oct 2017 Preclinical data for Non-alcoholic steatohepatitis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 18 Oct 2017 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US FDA recommends approval of semaglutide for Type-2 diabetes mellitus in USA
  • 29 Sep 2017 Novo Nordisk initiates enrolment in a phase I trial for Type-2 diabetes mellitus (In volunteers) in China (NCT03288740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top